MorphoSys’s Licensing Partner GSK Initiates Phase 3 Clinical Program With Otilimab (MOR103/GSK3196165) in Rheumatoid Arthritis; MorphoSys Updates its Financial Guidance for 2019
PLANEGG and MUNICH, GERMANY / ACCESSWIRE / July 3, 2019 / MorphoSys AG (FSE: MOR; Prime Standard Segment, MDAX &...